Frovatriptan Succinate Intranasal Delivery for Brain Targeting - In Vivo Study

Abstract

Muco-adhesive gel formulations are advantageous in extending the stay at the nasal absorption place, promoting drug absorption. Frovatriptan succinate (FVT) exhibits a 35% oral bioavailability and undergoes hepatic metabolism, making it a viable candidate for nasal delivery. This study aimed to assess novel FVT intranasal formulation for brain targeting in rat animal models. A total of 78 female rats (Rattus norvegicus domestica, Wister albino rats) were randomly divided into three groups: group A (considered a negative control), group B (includes 36 rats given FVT IV solution), and group C (includes 36 rats given FVT binary ethosome in situ gel intranasally). Drug levels in plasma and brain tissue were measured using HPLC methods. In all periods, for both brain tissue concentrations of FVT and the brain-to-plasma ratio of FVT, it was significantly higher in Group C compared to Group B. Nasal administration of FVT showed higher brain Tmax, Cmac, and AUC compared to IV administration, with 239.83% higher accumulation of FVT when nasal formulation used compared to IV administration. In conclusion, in situ gel has demonstrated its efficacy in facilitating the delivery of frovatriptan succinate via the nasal route. The convenience of the administration process, combined with reduced frequency of administration, contributes to improved patient adherence.